OCC · ASX

Orthocell Ltd (ASX:OCC)

AU$1.3

 -0.06 (-4.428%)
ASX:Live
17/04/2025 04:10:20 PM
HALO Ords GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

OCC Overview

OCC Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Neutral

Earnings

Strong

Growth

Earnings

Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About OCC

Website

Orthocell Ltd

Telephone

61.8.9360.2888

Address

Building 191 90 South Street Murdoch University Murdoch, Western Australia (WA) 6150

Description

Orthocell Ltd. engages in the business of developing and commercializing biological medical devices and cell therapies. Its products include CelGro, which is a naturally derived collagen medical device for soft tissue repair; and Antilogous Tenocyte Implantation for chronic treatment resistant tendon injuries. The company was founded by Paul Frederick Anderson and Ming Hao Zheng on March 21, 2006 and is headquartered in Murdoch, Australia.

OCC Price Chart

Key Stats

Market Cap

AU$327.88M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.35 - 1.79

Trade Value (12mth)

AU$255,411.00

1 week

-8.8%

1 month

-10.38%

YTD

-10.69%

1 year

240.79%

All time high

1.79

Key Fundamentals

EPS 3 yr Growth

-26.40%

EBITDA Margin

-210.00%

Operating Cashflow

-$7m

Free Cash Flow Return

-112.10%

ROIC

-123.80%

Interest Coverage

N/A

Quick Ratio

4.10

Other Data

Shares on Issue (Fully Dilluted)

216m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.06

OCC Announcements

Latest Announcements

Date Announcements

14 April 25

Quarterly Activity Report & Appendix 4C

×

Quarterly Activity Report & Appendix 4C

10 April 25

Remplir Regulatory Application Submitted for Hong Kong

×

Remplir Regulatory Application Submitted for Hong Kong

09 April 25

Regulatory Approval for Striate in US$65M Brazilian Market

×

Regulatory Approval for Striate in US$65M Brazilian Market

04 April 25

Remplir Cleared to Commence Sales in US$1.6B US Market

×

Remplir Cleared to Commence Sales in US$1.6B US Market

04 April 25

Investor Presentation - US FDA 510(k) Clearance for Remplir

×

Investor Presentation - US FDA 510(k) Clearance for Remplir

04 April 25

Orthocell Webinar Details - Remplir US FDA 510(k) Clearance

×

Orthocell Webinar Details - Remplir US FDA 510(k) Clearance

03 April 25

Trading Halt

×

Trading Halt

02 April 25

Orthocell to Present at HealthInvest Summit

×

Orthocell to Present at HealthInvest Summit

27 March 25

Application for quotation of securities - OCC

×

Application for quotation of securities - OCC

26 March 25

First Sales of Striate in Germany, Austria & Swiss Region

×

First Sales of Striate in Germany, Austria & Swiss Region

18 March 25

Regulatory approval to commence Striate sales in Singapore

×

Regulatory approval to commence Striate sales in Singapore

17 March 25

Notification regarding unquoted securities - OCC

×

Notification regarding unquoted securities - OCC

07 March 25

S&P DJI Announces March 2025 Quarterly Rebalance

×

S&P DJI Announces March 2025 Quarterly Rebalance

04 March 25

Notification regarding unquoted securities - OCC

×

Notification regarding unquoted securities - OCC

03 March 25

Application for quotation of securities - OCC

×

Application for quotation of securities - OCC

03 March 25

Cleansing Notice

×

Cleansing Notice

28 February 25

Application for quotation of securities - OCC

×

Application for quotation of securities - OCC

26 February 25

Orthocell Webinar Presentation

×

Orthocell Webinar Presentation

25 February 25

Orthocell Webinar

×

Orthocell Webinar

24 February 25

Appendix 4D & Half-Year Financial Report

×

Appendix 4D & Half-Year Financial Report

21 February 25

Remplir FDA Application submitted for US$84M Thai Market

×

Remplir FDA Application submitted for US$84M Thai Market

18 February 25

Application for quotation of securities - OCC

×

Application for quotation of securities - OCC

18 February 25

Cleansing Notice

×

Cleansing Notice

03 February 25

Remplir Regulatory Application Submitted for Canada

×

Remplir Regulatory Application Submitted for Canada

22 January 25

Strong Sales Drives Acceleration of Remplir Global Expansion

×

Strong Sales Drives Acceleration of Remplir Global Expansion

OCC Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.05 -0.03 -0.04 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.05 -0.03 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock 3.3 32.3 -12.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.04 -0.02 -0.02 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 0.07 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -89.7 61.8 -36.5 Lock Lock Lock
     Yield % Lock Lock Lock Lock -8.6 20.3 -10.4 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.05 0.03 0.02 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.04 0.03 0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock -46.1 -42.2 -34.5 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 195 197 202 Lock Lock Lock
Basic m Lock Lock Lock Lock 195 197 202 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 2 4 5 Lock Lock Lock
     Growth % Lock Lock Lock Lock 50.5 177.0 25.3 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 12 13 15 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 1 3 4 Lock Lock Lock
     Growth % Lock Lock Lock Lock 177.6 267.6 19.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock 54.4 72.1 68.8 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 46 28 31 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -11 -10 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.5 12.7 -14.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -729.6 -229.9 -210.0 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -12 -10 -12 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1.2 10.5 -13.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -752.4 -243.0 -219.8 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -11 -9 -10 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -3 -3 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -9 -6 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -0.8 31.4 -14.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -594.5 -147.3 -135.1 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -6 15 -7 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -1 -1 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 1 0 3 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -7 14 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -41.6 306.2 -153.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -4.4 3.3 -1.4 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 11 25 21 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 38 30 27 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -11 -24 -20 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 28 23 22 Lock Lock Lock
Equity $m Lock Lock Lock Lock 10 6 5 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 10 7 5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -40.8 -36.5 -22.3 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -24.0 -21.1 -27.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -91.9 -101.6 -158.4 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -82.6 -120.4 -195.8 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -65.8 -74.3 -123.8 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -45.3 173.5 -112.1 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock N/A -319.1 N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.9 2.5 1.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -106.2 -394.5 -439.6 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 5.2 5.9 4.3 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 5.1 5.7 4.1 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 31.3 92.4 89.6 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -91.8 322.1 -122.6 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.1 0.3 5.2 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 1.3 1.4 1.5 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.1 0.2 0.3 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 214.3 20.6 25.5 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.1 0.2 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.1 0.2 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -734.5 -221.8 -192.5 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -29.7 -31.8 -38.4 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -24.0 -21.1 -27.0 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 3.8 4.8 5.9 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -91.9 -101.6 -158.4 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -91.9 -101.6 -158.4 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 282.5 254.3 243.2 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 2,837.0 1,049.1 70.4 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 3,119.6 1,303.4 313.6 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 902.8 473.4 225.8 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 2,216.8 830.0 87.7 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

%

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.06%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

0.10%

3 Month Change

0.10%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

OCC Shortsell

Frequently Asked Questions

The current share price of Orthocell Ltd (OCC:ASX) is AU$1.3.
The 52-week high share price for Orthocell Ltd (OCC:ASX) is AU$1.79.
The 52-week low share price for Orthocell Ltd (OCC:ASX)? is AU$0.35.
Orthocell Ltd (OCC:ASX) does not pay a dividend.
Orthocell Ltd (OCC:ASX) does not pay a dividend.
Orthocell Ltd (OCC:ASX) does not offer franking credits.
Orthocell Ltd (OCC:ASX) is classified in the Healthcare.
The current P/E ratio for Orthocell Ltd (OCC:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.